Lakefront Biotherapeutics NV current report, Q1 FY2021

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV, a foreign private issuer, for the month of January 2021. The filing, dated January 6, 2021, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports on Form 20-F. Note: The input metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative performance data.

Material Changes

The filing does not disclose material changes in financial position or operations compared to prior periods. The content is limited to the announcement of a press release.

Guidance, Outlook, and Risks

Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed within the body of this Form 6-K. These details, if any, are contained within the attached press release (Exhibit 99.1), the text of which is not included in the provided input.

Investor Verification Checklist

  • Verify the specific content of the press release dated January 6, 2021, referenced as Exhibit 99.1.
  • Confirm the discrepancy between the metadata company name ("Lakefront Biotherapeutics NV") and the filing registrant ("Galapagos NV").
  • Review the incorporated Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.